pyrazines has been researched along with Chromosomal Translocation in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (25.93) | 29.6817 |
| 2010's | 20 (74.07) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Breccia, M; Colafigli, G; Massaro, F; Molica, M | 1 |
| Rajkumar, SV | 1 |
| Bergsagel, PL; Chesi, M | 1 |
| Arakaki, H; Uchihara, JN | 1 |
| Cashen, A; Cheng, EH; DiPersio, J; Hsieh, JJ; Kunkle, L; Liu, H; Pham, CG; Piwnica-Worms, DR; Vij, R; Westergard, TD | 1 |
| Anderson, KC; Bianchi, G; Richardson, PG | 1 |
| Vincent Rajkumar, S | 1 |
| Benner, A; Bochtler, T; Goldschmidt, H; Granzow, M; Hegenbart, U; Ho, AD; Hose, D; Jauch, A; Kimmich, C; Kunz, C; Schönland, SO; Seckinger, A | 1 |
| Dispenzieri, A; Warsame, R | 1 |
| Benner, A; Bochtler, T; Hegenbart, U; Kunz, C; Schönland, SO | 1 |
| Chen, LJ; Li, JY; Lu, H; Lu, SF; Shen, WY; Wang, LX | 1 |
| Palumbo, A; Rajkumar, SV | 1 |
| Berdel, WE; Bisping, G; Gustavus, D; Hilberg, F; Kienast, J; Kropff, M; Mesters, RM; Müller-Tidow, C; Munzert, G; Roth, GJ; Stefanic, M; Stelljes, M; Volpert, S; Wenning, D | 1 |
| San Miguel, J | 1 |
| Kulharya, A; Shah, R; Ustun, C; Yuan, J | 1 |
| Attal, M; Avet-Loiseau, H; Benboubker, L; Caillot, D; Campion, L; Facon, T; Guerin-Charbonnel, C; Harousseau, JL; Hulin, C; Kolb, B; Leleu, X; Macro, M; Marit, G; Mathiot, C; Minvielle, S; Moreau, P; Roussel, M; Stoppa, AM; Voillat, L; Wetterwald, M | 1 |
| Choo, C; Goh, YT; Hwang, W; Lao, ZT; Lau, LC; Lee, LH; Lee, YS; Lim, A; Lim, TH; Premalatha, P; Su, S; Tan, D; Teoh, G; Wee, HC; Wee, N; Yap, KC | 1 |
| Arnulf, B; Asli, B; Belhadj, K; Bories, JC; Bouscary, D; Brouet, JC; Chandesris, O; Choquet, S; Fermand, JP; Ghez, D; Hermine, O; Karlin, L; Macro, M; Malphettes, M; Porcher, R; Soulier, J | 1 |
| Du, ZX; Gao, YY; Liu, BQ; Meng, X; Niu, XF; Wang, HQ; Yan, Y; Zhang, HY | 1 |
| Chen, SJ; Chen, YL; Chen, Z; Cheng, X; Fang, HT; Feng, TT; Gao, L; Hu, ZG; Liu, Z; Ma, L; Pan, XF; Sheng, GQ; Xie, J; Yang, Y; Yu, XJ; Zhang, B; Zhang, FX; Zhao, HX; Zhen, T; Zhou, GB | 1 |
| Befani, CD; Daliani, DD; Hatzidaki, E; Liakos, P; Moutzouris, G; Papandreou, CN; Patrikidou, A; Tsapakidis, K; Vlachostergios, PJ; Voutsadakis, IA | 1 |
| Bauer, F; Codreanu, I; Dasanu, CA; Padmanabhan, P; Rampurwala, M | 1 |
| Allen, JE; Aqui, N; Dicker, DT; Dolloff, NG; El-Deiry, WS; Malysz, J; Talamo, G; Vogl, D | 1 |
| Locke, FL; Morgan, GJ | 1 |
| Cho, IJ; Kang, KW; Kim, SG; Lee, CH | 1 |
| Chang, H; Qi, X; Reece, D; Stewart, KA; Trieu, Y; Xu, W | 1 |
| Berges, C; Daniel, V; Fuchs, D; Haberstock, H; Miltz, M; Naujokat, C; Opelz, G; Sadeghi, M | 1 |
6 review(s) available for pyrazines and Chromosomal Translocation
| Article | Year |
|---|---|
Novel tyrosine-kinase inhibitors for the treatment of chronic myeloid leukemia: safety and efficacy.
Topics: Amino Acid Substitution; Benzamides; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation, Missense; Protein Kinase Inhibitors; Pyrazines; Translocation, Genetic | 2018 |
Molecular pathogenesis of multiple myeloma: basic and clinical updates.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Proliferation; Chromosomes, Human; Cyclin D; Disease-Free Survival; Gene Expression Regulation, Neoplastic; Humans; Immunoglobulin M; Incidence; Multiple Myeloma; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-myc; Pyrazines; ras Proteins; Risk Factors; Sex Factors; Somatic Hypermutation, Immunoglobulin; Survival Rate; Translocation, Genetic; Trisomy; United States | 2013 |
Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosomes, Human; Cyclophosphamide; Dexamethasone; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Practice Guidelines as Topic; Pyrazines; Risk Assessment; Thalidomide; Translocation, Genetic | 2014 |
Treatment of newly diagnosed myeloma.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Deletion; Clinical Trials as Topic; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Middle Aged; Multiple Myeloma; Myeloma Proteins; Prognosis; Pyrazines; Risk; Thalidomide; Translocation, Genetic; Transplantation Conditioning | 2009 |
Characteristics, pathogenesis, and novel treatments for multiple myeloma.
Topics: Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Translocation, Genetic | 2004 |
What is the evidence for the use of bisphosphonate therapy in newly diagnosed multiple myeloma patients lacking bone disease?
Topics: Bone Diseases; Boronic Acids; Bortezomib; Dexamethasone; Diphosphonates; Fatigue; Fractures, Bone; Humans; Imidazoles; In Situ Hybridization, Fluorescence; Lenalidomide; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Proteinuria; Pyrazines; Randomized Controlled Trials as Topic; Thalidomide; Time Factors; Translocation, Genetic; Treatment Outcome; Zoledronic Acid | 2012 |
21 other study(ies) available for pyrazines and Chromosomal Translocation
| Article | Year |
|---|---|
Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Disease Management; Drug Administration Routes; Drug Administration Schedule; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Plasma Cells; Prognosis; Pyrazines; Recurrence; Risk; Thalidomide; Translocation, Genetic; Transplantation, Autologous | 2013 |
[The appearance of t(9;22)(q34;q11.2) in BJP-λ type multiple myeloma during maintenance therapy including lenalidomide].
Topics: Bence Jones Protein; Boronic Acids; Bortezomib; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide; Translocation, Genetic | 2013 |
Proteasome inhibitors evoke latent tumor suppression programs in pro-B MLL leukemias through MLL-AF4.
Topics: Adult; Animals; Apoptosis; Boronic Acids; Bortezomib; DNA-Binding Proteins; G2 Phase Cell Cycle Checkpoints; Histone-Lysine N-Methyltransferase; Humans; M Phase Cell Cycle Checkpoints; Mice; Myeloid-Lymphoid Leukemia Protein; Nuclear Proteins; Oncogene Proteins, Fusion; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proteasome Inhibitors; Pyrazines; RNA, Small Interfering; Transcriptional Elongation Factors; Transfection; Translocation, Genetic | 2014 |
Best treatment strategies in high-risk multiple myeloma: navigating a gray area.
Topics: Antineoplastic Combined Chemotherapy Protocols; Back Pain; Biopsy; Bone Density Conservation Agents; Bone Marrow; Boronic Acids; Bortezomib; Dexamethasone; Diphosphonates; Fatigue; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Immunoglobulin G; Immunoglobulin lambda-Chains; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pyrazines; Referral and Consultation; Thalidomide; Translocation, Genetic; Transplantation, Autologous; Zoledronic Acid | 2014 |
Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens.
Topics: Adult; Aged; Amyloidosis; Boronic Acids; Bortezomib; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 4; Cyclophosphamide; Dexamethasone; Female; Humans; Immunoglobulin Light Chains; In Situ Hybridization, Fluorescence; Male; Middle Aged; Prognosis; Pyrazines; Retrospective Studies; Translocation, Genetic; Treatment Outcome | 2015 |
Blaming the Right Fluorescent in Situ Hybridization.
Topics: Amyloidosis; Boronic Acids; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 4; Dexamethasone; Female; Humans; Male; Pyrazines; Translocation, Genetic | 2015 |
Reply to R. Warsame et al.
Topics: Amyloidosis; Boronic Acids; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 4; Dexamethasone; Female; Humans; Male; Pyrazines; Translocation, Genetic | 2015 |
Bortezomib in combination with dexamethasone for a young multiple myeloma with t(8; 14).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 8; Dexamethasone; Fractures, Bone; Humans; Humerus; In Situ Hybridization, Fluorescence; Male; Multiple Myeloma; Pyrazines; Translocation, Genetic | 2009 |
Bortezomib, dexamethasone, and fibroblast growth factor receptor 3-specific tyrosine kinase inhibitor in t(4;14) myeloma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Cell Line, Tumor; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 4; Dexamethasone; Enzyme Inhibitors; Fibroblast Growth Factor 3; Humans; In Situ Hybridization, Fluorescence; Multiple Myeloma; Mutation; Protein-Tyrosine Kinases; Pyrazines; Translocation, Genetic | 2009 |
Near-tetraploidy clone can evolve from a hyperdiploidy clone and cause resistance to lenalidomide and bortezomib in a multiple myeloma patient.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Deletion; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 8; Clone Cells; Combined Modality Therapy; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Karyotyping; Lenalidomide; Middle Aged; Multiple Myeloma; Neoplastic Stem Cells; Peripheral Blood Stem Cell Transplantation; Polyploidy; Protease Inhibitors; Pyrazines; Thalidomide; Translocation, Genetic; Transplantation, Autologous | 2010 |
Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Chromosome Deletion; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 4; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; France; Hematopoietic Stem Cell Transplantation; Humans; In Situ Hybridization, Fluorescence; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Neoadjuvant Therapy; Prospective Studies; Protease Inhibitors; Pyrazines; Time Factors; Translocation, Genetic; Treatment Outcome; Vincristine | 2010 |
An abnormal nonhyperdiploid karyotype is a significant adverse prognostic factor for multiple myeloma in the bortezomib era.
Topics: Adult; Aged; Aged, 80 and over; Aneuploidy; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Cohort Studies; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Karyotyping; Male; Metaphase; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Pyrazines; Retrospective Studies; Salvage Therapy; Translocation, Genetic; Transplantation, Autologous; Treatment Outcome | 2010 |
Clinical and biological features of t(4;14) multiple myeloma: a prospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 4; Female; Flow Cytometry; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Pyrazines; Receptor, Fibroblast Growth Factor, Type 3; Salvage Therapy; Survival Rate; Translocation, Genetic | 2011 |
Proteasome inhibition induces a p38 MAPK pathway-dependent antiapoptotic program via Nrf2 in thyroid cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Glutamate-Cysteine Ligase; Glutathione; Humans; Microscopy, Confocal; NF-E2-Related Factor 2; p38 Mitogen-Activated Protein Kinases; Plasmids; Proteasome Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA; RNA, Small Interfering; Signal Transduction; Thyroid Neoplasms; Transcriptional Activation; Translocation, Genetic | 2011 |
Bortezomib interferes with C-KIT processing and transforms the t(8;21)-generated fusion proteins into tumor-suppressing fragments in leukemia cells.
Topics: Apoptosis; Boronic Acids; Bortezomib; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Humans; Leukemia; Phosphorylation; Protein Binding; Proto-Oncogene Proteins c-kit; Pyrazines; Translocation, Genetic | 2012 |
Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cells.
Topics: Antineoplastic Agents; Apoptosis; bcl-Associated Death Protein; Bombesin; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Down-Regulation; Endothelin-1; Humans; Interleukin-8; Male; Mitogen-Activated Protein Kinases; NF-kappa B; Prostatic Neoplasms; Proteasome Endopeptidase Complex; Pyrazines; RNA, Messenger; Signal Transduction; Translocation, Genetic; Tumor Suppressor Protein p53; Vascular Endothelial Growth Factor A | 2012 |
Plasmablastic haemato-lymphoid neoplasm with a complex genetic signature of Burkitt lymphoma responding to bortezomib.
Topics: Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Burkitt Lymphoma; Fatal Outcome; Genes, myc; Herpesvirus 4, Human; Humans; Immunoglobulin M; Lymphoma, Large B-Cell, Diffuse; Male; Neoplasms, Second Primary; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyrazines; Retroperitoneal Neoplasms; Transcriptome; Translocation, Genetic | 2013 |
Sangivamycin-like molecule 6 exhibits potent anti-multiple myeloma activity through inhibition of cyclin-dependent kinase-9.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Cyclin-Dependent Kinase 9; Drug Screening Assays, Antitumor; Flavonoids; Humans; Mice; Multiple Myeloma; Oncogenes; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrimidine Nucleosides; Translocation, Genetic; Treatment Outcome; Tubercidin | 2012 |
Essential role of phosphatidylinositol 3-kinase-dependent CCAAT/enhancer binding protein beta activation in the induction of glutathione S-transferase by oltipraz.
Topics: Animals; Anticarcinogenic Agents; Bacterial Proteins; Blotting, Northern; Carrier Proteins; CCAAT-Enhancer-Binding Protein-beta; Cell Line; Electrophoretic Mobility Shift Assay; Enzyme Induction; Gene Deletion; Gene Expression Regulation, Enzymologic; Genes, Reporter; Glutathione Transferase; Hepatocytes; Immunoblotting; Immunohistochemistry; Intracellular Signaling Peptides and Proteins; Luciferases; MAP Kinase Kinase 1; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase Kinases; Phosphatidylinositol 3-Kinases; Phosphorylation; Plasmids; Protein Serine-Threonine Kinases; Pyrazines; Rats; Rats, Inbred Strains; RNA, Messenger; Thiones; Thiophenes; Transfection; Translocation, Genetic; Up-Regulation | 2003 |
Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Carrier Proteins; CDC2-CDC28 Kinases; Chromosome Deletion; Cyclin-Dependent Kinases; Disease-Free Survival; Female; Gene Amplification; Humans; In Situ Hybridization, Fluorescence; Male; Middle Aged; Multiple Myeloma; Pilot Projects; Pyrazines; Retrospective Studies; Risk Factors; Salvage Therapy; Survival Rate; Translocation, Genetic | 2007 |
Proteasome inhibition suppresses essential immune functions of human CD4+ T cells.
Topics: Acetylcysteine; Antigens, CD; Apoptosis; Boronic Acids; Bortezomib; CD4-Positive T-Lymphocytes; Cell Cycle; Cell Cycle Proteins; Cell Proliferation; Cells, Cultured; Cytokines; Dose-Response Relationship, Immunologic; Humans; Immunosuppressive Agents; Lymphocyte Activation; NFATC Transcription Factors; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Translocation, Genetic; Tumor Suppressor Protein p53 | 2008 |